Barrx™ Treatment Reduces Risk of Developing Cancer
More than 12.5 million people in the U.S. have Barrett’s esophagus, many of whom do not know they have it. Barrett’s esophagus occurs when cells in the lower esophagus are affected by chronic exposure to acid. Because of its strong association with esophageal cancer, Barrett’s esophagus is considered a pre-cancerous disease.
Palmdale Regional Medical Center is pleased to offer the Barrx™ radiofrequency ablation system, a treatment that removes precancerous tissue (dysplastic Barrett’s esophagus) in patients with Barrett’s esophagus. Patients who undergo treatment with the Barrx™ radiofrequency ablation system may reduce the risk of their disease progressing to esophageal cancer by more than 90 percent.
Because Barrett’s esophagus is a precursor to esophageal cancer, timely detection and treatment are essential. We encourage people diagnosed with gastroesophageal reflux disease (GERD) or anyone who has experienced symptoms of acid reflux to schedule a consultation, as they may be at risk for Barrett’s esophagus.